Journal of inflammation research
Cure8 research brief
Why This Matters
If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests and treatments in the future.
Who Should Pay Attention
Patients on or failing anti‑TNF therapy, gastroenterologists, and researchers focused on immune pathways and biomarkers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review summarizes mechanisms thought to cause resistance to TNF-α (anti‑TNF) drugs in ulcerative colitis and highlights potential drug targets and precision-medicine approaches.
The authors review pharmacodynamic drivers of non‑response beyond low drug levels or antibodies — for example activation of IL‑6, oncostatin M, IL‑23/Th17 pathways, IL‑1–mediated innate responses, myeloid and B‑cell signatures, neutrophil extracellular traps, and microbiome-related metabolic changes.
They note that advances in transcriptomics and single‑cell sequencing show multiple inflammatory “pathotypes” that may explain heterogeneous responses to anti‑TNF therapy.
The paper frames these mechanisms as possible avenues to: (1) guide therapeutic sequencing for patients who fail anti‑TNF drugs, (2) optimize existing treatments, and (3) identify novel combination or next‑generation targets. It emphasizes that many emerging mechanisms are biologically plausible but require further clinical validation.
Keep In Mind
This is a review article (abstract-level summary). It synthesizes existing studies and highlights hypotheses and promising targets, but does not report new clinical trial results; clinical applicability of many mechanisms is still unproven.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of inflammation research
AuthorsFairweather M, Faggiani I, Ma C
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 26, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Single-cell transcriptomic analysis reveals that Trametes robiniophila Murr. (Huaier) granules protect against ulcerative colitis by targeting macrophage-associated cGAS-STING signaling.
The study describes a mechanism by which Huaier granules reduced colitis-related inflammation in mice and cell models by targeting macrophage cGAS–STING signaling and altering the gut microbiome—information that could...
Multi-omics analysis identifies fibroblast IGFBP5 as a key target of anti-TNFα therapy in ulcerative colitis
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Tissue-resident Granzyme K+ CD8 T cells fuel Crohn's - Bioengineer.org
If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...